A recent increase in the literature regarding the evidence base for clozapine has made it
increasingly difficult for clinicians to judge “best evidence” for clozapine use. As such, we …

We summarized and compared meta-analyses of pharmacological and non-
pharmacological interventions targeting physical health outcomes among people with …

Abstract About 40%-70% of the patients with treatment-resistant schizophrenia have a poor
response to adequate treatment with clozapine. The impact of clozapine-resistant …

The long-term treatment of patients with schizophrenia often involves the management of
relapses for most patients and the development of treatment resistance in some patients. To …

Background: Two distinct subtypes of treatment-resistant schizophrenia (TRS) have been
recently reported, including early-treatment resistance (E-TR) and late-treatment resistance …

Background Sedation is a common and incapacitating clozapine adverse effect, but the
factors associated with sedation and its pharmacological management remain poorly …

Introduction: Despite treatment with antipsychotic medication, approximately 1/3 of
individuals with schizophrenia will fail to have an adequate response. To treat these …

Little is understood about the prescription load before and after the starting of clozapine.
Accordingly, this study aimed to evaluate the medication load of patients receiving …

Abstract Background Antipsychotic-induced Weight Gain (AiWG) is a debilitating and
common adverse effect of antipsychotics. AiWG negatively impacts life expectancy, quality of …